Exhibit 10.12
ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT
ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT dated as of October 7, 1999
(the "Agreement") by and between IMARX, LLC, an Arizona limited liability
company ("Purchaser") and IMARX PHARMACEUTICAL CORP., an Arizona corporation
("Seller"). Capitalized terms used but not otherwise defined herein have the
meanings assigned to them in the Technology Agreements (as defined below).
RECITALS
A. Seller is engaged in the research and development of pharmaceutical
products. Among other assets, Seller owns certain patents and patent
applications in the field of ultrasound diagnostic imaging. Seller has
previously assigned and/or licensed certain of its patents and patent
applications to DuPont Pharmaceuticals Company ("DuPont") pursuant to the
Assignment and License Agreement dated October 23, 1995 and the License and
Marketing Agreement dated October 23, 1995, and amendments thereto (hereinafter
collectively referred to as the "Technology Agreements").
▇. ▇▇▇▇▇▇ has made an offer to acquire the stock of Seller, provided that
Seller divests itself of certain assets and liabilities. The parties anticipate
that Seller will be merged into a subsidiary of DuPont (the "Merger") pursuant
to an Agreement and Plan of Merger (the "Acquisition Agreement").
C. Purchaser will assume all liabilities of Seller other than those
liabilities specifically retained by Seller and accepted by DuPont in the
Acquisition Agreement (the "Assumed Liabilities"). Purchaser wishes to acquire
certain assets of Seller (including the "Physical Assets and Receivables" and
the "Category III Assets") identified on Exhibit A. Seller wishes to license the
Category III Assets back from Purchaser for use within the field of contrast
enhancement of diagnostic ultrasound imaging, but specifically excluding
targeted and tissue specific diagnostic ultrasound products. This field of use
is referred to herein as "CEDUI."
D. Purchaser wishes to license from Seller certain assets to be acquired by
DuPont in connection with the Acquisition Agreement (the "Category II Assets")
identified on Exhibit B for use outside of CEDUI.
E. Seller wishes to secure from Purchaser a right of first negotiation with
respect to new products developed by Purchaser in the fields of thrombus imaging
and sonothrombolysis.
F. The parties wish to agree on certain procedures and responsibilities for
addressing certain claims of infringement that may arise from Seller's practice
of its technology.
G. The execution and delivery of this Agreement by Purchaser is a condition
to the obligations of Seller to consummate the transactions contemplated by the
Acquisition Agreement.
AGREEMENT
NOW, THEREFORE, in consideration of the foregoing premises and of the
agreements and covenants set forth in the Acquisition Agreement, Purchaser and
Seller agree as follows:
1. Assignment of Assets.
a. Seller hereby grants, conveys, sells, transfers and assigns to
Purchaser, free and clear of all debts, obligations, liens and
encumbrances (other than the Assumed Liabilities, as that term is
defined below) all of the assets described on Exhibit A hereto;
provided, however, that the Category III Assets shall not include any
Assets to be acquired by DuPont in the Merger.
b. Seller hereby assigns to Purchaser its rights under the Assigned
Patents, as that term is defined in the Technology Agreements, which
rights are fully set forth and described in Section 3 of the
Assignment and License Agreement dated October 23, 1995. Purchaser's
license rights granted therein will survive any termination,
cancellation, or modification of the Assignment and License Agreement
by Seller.
2. Assignment of Name. Effective as of the date of Closing pursuant to the
Acquisition Agreement, Seller hereby assigns the name "ImaRx
Pharmaceuticals" along with any variations thereof to Purchaser along with
the goodwill associated with the Category III Assets. Seller will execute
any additional documents necessary to transfer the name to Purchaser.
3. Assumption of Liabilities. Seller hereby assigns to Purchaser, and
Purchaser hereby assumes and agrees to pay, perform and discharge, and to
indemnify Seller against and hold it harmless from all of the liabilities
and obligations of Seller accrued or arising before the Closing (as that
term is described in the Acquisition Agreement), including without
limitation those Liabilities set forth on Exhibit D hereto (the "Assumed
Liabilities"); provided, however, that the Assumed Liabilities shall not
include any liabilities or obligations to be assumed by DuPont in the
Merger as provided in the Acquisition Agreement.
4. License by Seller. Seller hereby grants to Purchaser an exclusive,
transferable license to the Category II Assets, with right to sublicense,
to make, have made, import, use, and sell product derived from the Category
II Assets, worldwide, for every field of use outside of CEDUI. Seller also
grants to Purchaser the right to file and prosecute divisional applications
for patent claims relating solely to fields of use outside of CEDUI arising
from patent applications included within Category II Assets, provided that
Purchaser will be solely responsible for all costs and expenses incurred in
connection with such filing and prosecution and further provided that
Purchaser will have no right to practice, transfer, license, or otherwise
exploit any patents issuing from such applications within CEDUI. Seller
expressly retains all rights to the Category II Assets within CEDUI,
including, without limitation, all rights relating to the product
Definity(R), all related products (including, without limitation, MRX-421A1
and MRX-132), all back-up products, next-generation products, and
improvements thereto.
2
5. License by Purchaser. Upon assignment of the Category III Assets, Purchaser
grants to Seller an exclusive, transferable license to the Category III
Assets, with right to sublicense, to make, have made, import, use, and sell
products derived from the Category III Assets, worldwide, within CEDUI.
Purchaser expressly retains all rights to the Category III Assets outside
CEDUI.
6. Seller's Right of First Negotiation to Purchaser's Products. If Purchaser
develops products or technology in the area of thrombus imaging or
sonothrombolysis, (collectively, "New Product"), Purchaser will offer to
Seller an exclusive license to the New Product for development and
commercialization before offering the New Product to any third party for
license. In connection therewith, Purchaser will provide Seller with all
relevant information requested by Seller and reasonably available to
Purchaser concerning the New Product. Seller will then have ninety (90)
days within which to make an offer for the New Product. If Seller makes
such an offer, the parties will negotiate promptly and in good faith to
arrive at an agreement. If the parties fail to reach such an agreement
within a reasonable period, Purchaser may assign, license, or otherwise
transfer rights in the New Product to a third party, but only on terms that
are, on balance, not less favorable to Purchaser than the last written
offer of Seller, as reasonably determined by Purchaser, or may pursue
commercial development of the New Product on its own, at Purchaser's
election.
7. Representations and Warranties.
a. By Seller. Seller represents and warrants as follows:
(i) Seller is the sole owner of the Category II Assets and Category
III Assets and, subject to any limited rights that the U.S.
government might have, has the legal authority to assign the
Category III Assets and to license the Category II Assets to
Purchaser and otherwise to enter into and perform all of its
obligations set forth herein;
(ii) all corporate and other formalities necessary to authorize
execution, delivery and performance of this Agreement (and all
other documents executed and delivered in connection herewith) on
behalf of Seller have been taken; and
Seller makes no other warranties, express or implied, except as expressly
set forth in this Agreement. In particular, and without limitation, Seller makes
no implied or express warranties of noninfringement or validity or any other
representation or warranty whatsoever regarding Patents or Product.
b. By Purchaser. Purchaser represents and warrants as follows:
(i) Purchaser has the legal authority to accept the assignment of
Category III Assets and the license to Category II Assets granted
hereunder and otherwise to perform all of its obligations set
forth herein;
3
(ii) all LLC and other formalities necessary to authorize execution,
delivery and performance of this Agreement (and all other
documents executed and delivered in connection herewith) on
behalf of Purchaser have been taken.
Purchaser makes no other warranties, express or implied, except as expressly set
forth in this Agreement. In particular, and without limitation, Purchaser makes
no implied or express warranties of noninfringement or validity or any other
representation or warranty whatsoever regarding Patents or Product.
8. Intellectual Property Protection.
a. Claim of Infringement. If Purchaser discovers that a third party
claims that practice of the Category II Assets infringes a patent or
other intellectual property right of such third party, then Purchaser
will promptly so notify Seller and Seller shall have sole authority to
defend against or settle any such claim of infringement, provided that
no settlement will impair Purchaser's license granted by Section 4
above. If Seller discovers that a third party claims that practice of
the Category III Assets infringes a patent or other intellectual
property right of such third party, then Seller will promptly so
notify Purchaser and Purchaser shall have sole authority to defend
against or settle any such claim of infringement, provided that no
settlement will impair Seller's license granted by Section 5 above.
b. Infringement of Patents. If either party becomes aware that a third
party is or may be infringing the Patents, it shall promptly so notify
the other party. If the infringement related to Category II Assets,
Seller shall have authority to pursue a claim for infringement. If
Seller fails to resolve such infringement or institute an infringement
action against the third party within one hundred twenty (120) days
after Seller becomes aware of the infringement, Seller will assign its
rights to pursue the infringement to Purchaser. If there is
infringement related to Category III Assets, Purchaser shall have
authority to pursue a claim for infringement. If Purchaser fails to
resolve such infringement or institute an infringement action against
the third party within one hundred twenty (120) days after Purchaser
becomes aware of the infringement, then Purchaser shall assign its
rights to pursue the infringement to Seller.
9. Claim of Infringement of Sonus Patents. Notwithstanding anything to the
contrary contained in Section 8 above, the provisions of this Section 9
will apply to and govern any claim asserted (whether by litigation or
otherwise) by Sonus Pharmaceuticals, Inc. and/or its licensees or assignees
(collectively, "Sonus") within five years of the date of this Agreement
that Seller's manufacture or sale of the product known as Definity(R)
infringes a patent or other intellectual property right of Sonus (a "Sonus
infringement claim"). If Seller receives a Sonus infringement claim, it
will promptly so notify Purchaser, and the parties will proceed as follows:
4
a. Seller will keep Purchaser informed of developments relevant to the
Sonus claim and will consider Purchaser's recommendations for
proceeding, although Seller will have the final authority;
b. Seller will use all commercially reasonable efforts to defeat or
resolve a Sonus claim, including but not limited to cross licensing
its diagnostic technology to Sonus;
c. Purchaser will use all commercially reasonable efforts in cooperation
with Seller and in support of Seller's efforts, including the
commitment of all reasonable amounts of ▇▇. ▇▇▇▇ ▇▇▇▇▇'▇ time, subject
to reimbursement by Seller of Purchaser's out of pocket costs (which
will not include the value of ▇▇. ▇▇▇▇▇'▇ time);
d. At Seller's election, if these commercially reasonable efforts fail to
resolve the Sonus claim and Seller believes it is at substantial risk
of losing the ability to manufacture or sell Definity(R) in a
commercially significant geographic market, Purchaser will grant to
Seller a transferable covenant not to ▇▇▇ Sonus for infringement of
Purchaser's Category III assets to the extent necessary to allow Sonus
to manufacture and sell its therapeutic products, provided that Seller
receives a reciprocal covenant from Sonus, which Seller will then
transfer to Purchaser;
e. The covenant referenced in Paragraph 9.d above will be drawn as
narrowly as possible to allow Sonus to manufacture and sell Sonus's
therapeutic products, and will not be construed as a license to allow
Sonus to manufacture or sell products developed by Purchaser or to
grant Sonus and rights in any safety or efficacy data developed by
Purchaser relating to those products; and
f. If Seller directs Purchaser to provide a covenant pursuant to
Paragraph 9.d, Seller will pay Purchaser the sum of $1.5 million in
partial compensation for Purchaser's delivery of the covenant.
10. Indemnification.
a. Seller shall indemnify, defend, and hold Purchaser harmless from any
and all claims, demands, lawsuits, and associated costs and expenses,
including reasonable attorneys' fees and cost of settlement, arising
out of Seller's manufacture, promotion, marketing, and sale of
products derived from or based on Category III Assets; provided,
however, that Seller shall not be obligated to indemnify, defend, and
hold Purchaser harmless where the claim, demand, lawsuit, and
associated costs and expenses, including reasonable attorneys' fees
and cost of settlement arises out of the breach of this Agreement by
Purchaser and further provided that Purchaser promptly notifies Seller
upon becoming aware of any such claims. Seller shall have the right to
conduct the defense of any such claim but if Seller fails after
reasonable notice from Purchaser to conduct such defense, Purchaser
shall have the right to do so and Seller will reimburse
5
Purchaser for all reasonable costs and expenses of defending the
action, including attorneys' fees and costs of settlement.
b. Purchaser shall indemnify, defend, and hold Seller harmless from any
and all claims, demands, lawsuits, and associated costs and expenses,
including reasonable attorneys' fees and cost of settlement, arising
out of Purchaser's manufacture, promotion, marketing, and sale of
products derived from or based on Category II Assets; provided
however, that Purchaser shall not be obligated to indemnify, defend,
and hold Seller harmless where the claim, demand, lawsuit, and
associated costs and expenses, including reasonable attorneys' fees
and cost of settlement arises out of the breach of this Agreement by
Seller and further provided that Seller promptly notifies Purchaser
upon becoming aware of any such claims. Purchaser shall have the right
to conduct the defense of any such claim but if Purchaser fails after
reasonable notice from Seller to conduct such defense, Seller shall
have the right to do so and Purchaser will reimburse Seller for all
reasonable costs and expenses of defending the action, including
attorneys' fees and costs of settlement.
11. Rights to Improvements in Product or Manufacturing. All assignments and
licenses hereunder include such rights to improvements as Seller has
received or is entitled to receive from DuPont pursuant to Section 5 of the
Assignment and License Agreement dated October 23, 1995, through the date
of the Closing of the Acquisition Agreement, to the extent that such
improvements apply outside the field of CEDUI.
12. Maintenance and Prosecution of Patents
a. Seller may elect not to prosecute or maintain a patent within the
Category II Assets if it reasonably concludes that such patent has no
significant value to Seller within the field of CEDUI. In that event,
it will so notify Purchaser. Purchaser will, within ninety (90) days
of receipt of such notice, notify Seller whether it wishes to acquire
the patent from Seller. During this ninety (90) day period, Seller
will take any action necessary to continue to prosecute or maintain
the patent. Purchaser will reimburse Seller for its out-of-pocket
costs incurred in such actions. Upon notice by Purchaser that it
wishes to acquire the patent from Seller, Seller will assign the
patent to Purchaser, transfer any files or other documents relating to
the patent to Purchaser, and Purchaser will thereafter be solely
responsible for prosecution or maintenance of the Patent, including
all costs associated therewith. Seller agrees to execute any
additional documents necessary to perfect Purchaser's rights to the
patent. Purchaser agrees that, upon transfer of the patent to
Purchaser, it will not assert any claim related to such paten against
Seller. If no notice is received by Seller within the ninety (90)
period, Seller will abandon the patent.
b. Purchaser may elect not to prosecute or maintain a patent within the
Category III Assets if it reasonably concludes that such patent has no
significant value to Purchaser outside the field of CEDUI. In that
event, it will so notify Seller. Seller will, within ninety (90) days
of receipt of such notice, notify Purchaser
6
whether wishes to acquire the patent from Purchaser. During this
ninety (90) day period, Purchaser will take any action necessary to
continue to prosecute or maintain the patent. Seller will reimburse
Purchaser for its out-of-pocket costs incurred in such actions. Upon
notice by Seller that it wishes to acquire the patent from Purchaser,
Purchaser will assign the patent to Seller, transfer any files or
other documents relating to the patent to Seller, and Seller will
thereafter be solely responsible for prosecution or maintenance of the
Patent, including all costs associate therewith. Purchaser agrees to
execute any additional documents necessary to perfect Seller's rights
to the patent. Seller agrees that, upon transfer of the patent to
Seller, it will not assert any claim related to such patent against
Purchaser. If no notice is received by Purchaser within the ninety
(90) period, Purchaser will abandon the patent.
H. Further Assurances. At any time, the parties shall execute such
additional instruments, provide such additional information and take such
additional action as may be reasonably requested by the other party to confirm
or perfect title to any property transferred hereunder or otherwise to carry out
the intent and purposes of this Agreement.
I. Arizona Law. The laws of the State of Arizona, without regard to its
conflict of laws principles, shall govern the validity of this Agreement, the
construction of its terms, and the interpretation of the rights and duties of
the Managers and Members. Pima County, Arizona shall be the exclusive proper
venue for any action brought under this Agreement.
J. Counterparts. This Agreement may be executed in two or more
counterparts, and by the different parties hereto in separate counterparts, each
of which when executed shall be deemed to be an original, but all of which taken
together shall constitute one and the same instrument.
K. Construction. Nothing expressed or implied in this Agreement is intended
to confer upon any person, other than Purchaser and Seller and their respective
successors and assigns, any rights, remedies, obligations or liabilities under
or by reason of this Agreement.
7
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the day and year first above written.
IMARX PHARMACEUTICAL CORP., IMARX LLC,
an Arizona corporation an Arizona limited liability company
By: /s/ ▇▇▇▇ ▇▇▇▇▇ By: /s/ ▇▇▇▇ ▇▇▇▇▇
--------------------------------- ------------------------------------
▇▇. ▇▇▇▇ ▇▇▇▇▇ ▇▇. ▇▇▇▇ ▇▇▇▇▇
Its: President Its: Manager
8
EXHIBIT A
PHYSICAL ASSETS AND RECEIVABLES AND CATEGORY III ASSETS
PHYSICAL ASSETS AND RECEIVABLES
1. Cash in the amount of $104,012.
2. All of the right, title and interest of ImaRx in that tangible personal
property set forth on Schedule 1, attached hereto and incorporated by
reference herein.
3. All of the inventories of ImaRx.
4. All accounts receivable of ImaRx as of the effective date of the Merger,
including trade accounts receivable.
5. All amounts receivable from the National Institutes of Health pursuant to a
grant awarded to ImaRx dated July 29, 1999.
6. All amounts receivable from employees of ImaRx as of the effective date of
the Merger.
7. All rights and privileges in and amounts receivable by ImaRx under that
certain agreement with BRAACO International and BRAACO Diagnostic Inc.
dated December 4, 1998.
CATEGORY III ASSETS
1. ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Pending - 08/942,862 (UNGR 1227)
2. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Pending - 08/741,598 (UNGR 0991), 09/052,075 (UNGR 1283)
3. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Pending - 08/947,305 (UNGR 1223)
4. UNGR 1172 family
United States - Pending - USSN 08/929,847 - first Office Action
Europe - Pending - UNGR 1501 (States: AT, BE, DK, FR, DE, GB, GR, IE, IT,
LU, NE, ES, SE, CH)
5. UNGR 1269 family
United States - Pending - USSN 08/982,829 - first Office Action
9
EXHIBIT B
CATEGORY II ASSETS
1. UNGR 0019 family
United States - Issued - 5,088,499 (UNGR-0019), 5,230,882 (UNGR-0095),
5,352,435 (UNGR-0279), 5,456,901 (UNGR-0574)
United States - Allowed - 08/665,719 (UNGR-0728), 08/888,426 (UNGR-1190)
Europe - UNGR 0029, 0628 (States: AT, BE, DK, FR, DE, GB, GR, IT, LU, NE,
ES, SE, CH/LU)
Japan - UNGR 0043
2. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,205,290 (UNGR-0046), 5,281,408 (UNGR-0295),
5,456,900 (UNGR-0346), 5,547,656 (UNGR-0664), 5,527,521 (UNGR-0665)
United States - Pending - 08/878,233 (UNGR-1174)
United States - Abandoned - UNGR 0875
Europe - UNGR 0099 (States: AT, BE, DK, FR, DE, GB, GR, IT, LU, MO, NE, ES,
SE, CH/LU)
Japan - UNGR 0114
3. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,305,757 (UNGR-0299), 5,348,016 (UNGR-0319)
United States - Pending - 09/000,522
4. ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,469,854 (UNGR-0298), 5,715,824 (UNGR-0686)
United States - Allowed - 08/758,179 (UNGR-0988)
Europe - UNGR 0448 (States: AT, BE, DK, FR, DE, GB, GR, IT, LU, NE, ES, SE,
CH/LU)
Japan - UNGR 0466
5. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,542,935 (UNGR-0348)
10
United States - Pending - 08/485,998 (UNGR-0692)
Europe - UNGR 0487 (States: AT, BE, DK, FR, DE, GB, GR, IT, LU, NE, ES, SE,
CH)
Japan - UNGR 0504
6. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,585,112 (UNGR-0350), 5,853,752 (UNGR-0685)
Europe - UNGR 0509 (States: AT, BE, DK, FR, DE, GB, GR, IE, IT, LU, NE, ES,
SE, CH)
Japan - UNGR 0526
7. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,5773,024 (UNGR-0480)
Europe - UNGR 0697 (States: AT, BE, DK, FR, DE, GB, GR, IE, IT, LU, NE, ES,
SE, CH)
Japan - UNGR 0714
8. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,705,187 (UNGR-0570)
Europe - UNGR 0889 (States: AT, BE, DK, FI, FR, DE, GB, GR, IE, IT, LU, MO,
NE, PT, ES, SE, CH)
Japan - UNGR 0906
9. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,656,211 (UNGR-0571)
United States - Pending - 08/833,489 (UNGR-1035)
Europe - UNGR 0815 (States: AT, BE, DK, FI, FR, DE, GB, GR, IE, IT, LU, MO,
NE, PT, ES, SE, CH)
Japan - UNGR 0832
10. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Allowed - 08/666,129 (UNGR-0725)
Europe - UNGR 1009 (States: FR, GB, DE, NE)
11
Japan - UNGR 1027
11. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Issued - 5,776,429 (UNGR-0733)
United States - Pending - 09/026,326 (UNGR 1286)
Europe - UNGR 1046 (States: AT, BE, DK, FI, FR, DE, GB, GR, IE, IT, LU, MO,
NE, PT, ES, SE, CH)
Japan - UNGR 1064
12. UNGR 1550 family
United States - Pending - USSN 09/243,640 - awaiting first Office Action;
not eligible for foreign filing until 2/3/2000
13. UNGR 0992 and 1030 - Interference applications
14. UNGR ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇ - Pending - UNGR 1032, 1192
12
EXHIBIT C
ASSUMED LIABILITIES
1. Promissory Note Payable to the order of ▇▇▇▇▇▇ ▇▇▇▇▇ dated September 30,
1998.
2. Promissory Note Payable to Bank One, N.A. dated April 10, 1999.
3. Master Finance Lease Payable to Zions Credit Corporation dated January 21,
1999.
4. All accounts payable by ImaRx as of the effective date of the Merger.
5. All accrued salaries, bonuses, and deferred employee compensation payable
by ImaRx as of the effective date of the Merger.
6. All income, sales, transaction privilege, use, excise, payroll and other
taxes payable by ImaRx to any government, governmental agency, or
subdivision thereof, as of the effective date of the Merger.
7. All other liabilities of ImaRx as of the date of the Merger, other than
those liabilities specifically retained by ImaRx and accepted by du Pont in
the Acquisition Agreement, as set forth in Section 3.11 of the Disclosure
Schedule to the Agreement and Plan of Merger.
13
AMENDMENT TO ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT
THIS AMENDMENT to the Assignment, Assumption and License Agreement dated as
of October 7, 1999 (the "Agreement") by and between IMARX, LLC, an Arizona
limited liability company ("Purchaser") and IMARX PHARMACEUTICAL CORP., an
Arizona corporation ("Seller") is entered into and effective this ___ day of
July, 2000 by and between IMARX THERAPEUTICS, INC., successor in interest to
Purchaser ("ImaRx") and DuPont Contrast Imaging, Inc. ("DuPont"), successor in
interest to Seller. Capitalized terms used but not otherwise defined herein have
the meanings assigned to them in the Agreement.
RECITALS
A. Purchaser and Seller entered into the Agreement as of October 7, 1999.
Thereafter, Seller was merged into DuPont.
B. Exhibit A and Exhibit B to the Agreement were incomplete. The parties
now wish to correct this error by amending Exhibit A and Exhibit B to conform to
the parties' original understanding.
NOW, THEREFORE, in consideration of the foregoing premises and of the
agreements and covenants set forth in the Agreement, the parties agree as
follows:
AGREEMENT
1. Assignment of Assets. Attached hereto is Exhibit E. Exhibit E sets forth
additional Category III Assets that were intended to be and hereby are
included in Exhibit A, effective as of the date of the Agreement. DuPont
will execute any other or further documents reasonably deemed necessary to
reflect the transfer of the assets set forth in Exhibit E to ImaRx in
accordance with the terms of the Agreement.
2. License of Assets. Attached hereto is Exhibit F. Exhibit F sets forth
additional Category II Assets that were intended to be and hereby are
included in Exhibit B, effective as of the date of the Agreement. The
Assets set forth in Exhibit F are subject to the license terms of Paragraph
4 of the Agreement, effective as of the date of the Agreement.
3. No Warranty. DuPont believes that it has not assigned, conveyed, licensed
or otherwise transferred any interest in any asset listed on Exhibit E to
any other person or entity. DuPont believes that it has not licensed or
otherwise transferred any interest in any asset listed on Exhibit F that
would conflict with or be contrary to the exclusive license to ImaRx as
provided in Paragraph 4 of the Agreement. Notwithstanding anything to the
contrary, DuPont makes no warranty, express or implied, regarding the
assets listed on Exhibit E and specifically disclaims any responsibility
for any action or inaction with respect to the assets, including action or
inaction with regard to the prosecution of any patents or any other
protection of any intellectual property embodied or reflected in Exhibit E
and Exhibit F during the period from the date of the Agreement to the date
of this Amendment.
-1-
4. Continued Effect. Except as amended hereby, the Agreement remains in full
force and effect.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of __________ the day and year first above written.
DUPONT CONTRAST IMAGING INC, IMARX THERAPEUTICS, INC.,
a Delaware general partnership an Arizona corporation
By: /s/ ▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇ By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇
--------------------------------- ------------------------------------
▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇ ▇▇. ▇▇▇▇ ▇▇▇▇▇
Its: Its: President
--------------------------------
-2-
EXHIBIT E
{ISSUED and PENDING US Patents followed by Foreign Files (if any)}
LUMENHANCE PATENT FAMILIES
WWKMN Docket Series (UNGR 0018 and UNGR 0026)
US 5,143,716; US 5,320,826; US 5,449,508; US 5,525,326; US 5,885,549
US 5,368,840; US 5,658,550; US 5,624,661; US 5,645,816; US 5,681,542
US 5,985,244
Other files: USSN 07/507,125 (abandoned)
USSN 09/198,202 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0018 and UNGR-0026)
Corresponding to UNGR-0018
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ EPO Application Number 91908011.9;
now EP Patent No. 0526503
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
UNGR-0055 France
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 507878/1991
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 51387/93; now ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 51387/93;
now ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,146,986
UNGR-0324 EPO App No. 93922369.9
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
-▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 510017/1994
UNGR-0670 EPO App. No. No. 95111117.8;
now European Patent No. 0693288
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-0675 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
UNGR-0678 Italy
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-0682 Sweden - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 70480/96;
now Australia Serial No. 687690
Corresponding to UNGR-0026
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 19005/92;
now ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,133,746
UNGR-0197 EPO App. No. 92911636.6
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
-▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-0205 Italy
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-0210 Sweden
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 510977/92
SONORX PATENT FAMILY
WWKMN Docket Series (UNGR 0020)
US 5,420,176; US 5,639,442; US 5,714,528; US 5,714,529; US 5,948,387
US 6,024,939
Pending: USSN 08/574,373
USSN 08/574,371
Other files: USSN 07/532,213 (abandoned)
USSN 07/708,731 (abandoned)
USSN 07/969,426 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0020)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,081,560 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 80858/91;
now Australia Serial No. 650466 (abandoned)
UNGR-0073 EPO App. No. 91910712.8;
now European Patent No. 0531421 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
-▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
UNGR-0085 Sweden (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇/▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 63196/94;
now Australia Serial No. 671538 (abandoned)
UNGR-0861 EPO App. No. 96104842.8 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
UNGR-0866 Great Britain (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 48195/96;
now Australia Serial No. 686047 (abandoned)
THERAPEUTIC AEROSOMES FAMILIES
WWKMN Docket Series UNGR 0023, UNGR 0067 and UNGR 0068)
US 5,149,319
US 5,209,720
US 5,580,575; US 5,770,222
Pending: USSN 09/060,396
Other files: USSN 07/716,899 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0023, UNGR-0067 and UNGR-0068)
Corresponding to UNGR-0023*
▇▇▇▇-▇▇▇▇ - ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 19926/92;
now Australia Serial ▇▇. ▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,118,016 (abandoned)
-▇-
▇▇▇▇-▇▇▇▇ EPO App. No. 92912400.6
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-0186 Italy
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-0191 Sweden
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 519204/93
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 91369/98 (abandoned)
* NOTE: The following foreign applications, although corresponding to the
U.S. patent application UNGR-0023, were not listed since they contain
subject matter which you have indicated was transferred to DuPont:
▇▇▇▇-▇▇▇▇, ▇▇▇▇▇▇▇▇▇ App. No. 12212/97; now Australia Serial No. 694973;
UNGR-1155 Canada App. No. 2,211,517;
UNGR-1156 EPO App. No. 97202273.5 (and its corresponding country files
UNGR-1157 to UNGR-1170);
UNGR-1171 Japan App. No. 184624/97.
Corresponding to UNGR-0067
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 21496/92;
now Australia Serial ▇▇. ▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,110,487 (abandoned)
UNGR-0138 EPO App. No. 92912455.0;
now ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇;
now Austria Patent No. AT E 172625 T1 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇;
-5-
now Germany Patent No. DE 692 27 468 T 2
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇;
now Greece Patent ▇▇. ▇▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ Monaco (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 500845/93;
now Japan Patent No. ▇▇▇▇▇▇▇
Corresponding to UNGR-0068
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 20238/92;
now ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,110,490
UNGR-0157 EPO App. No. 92912662.1
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-0165 Italy
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-0170 Sweden
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 500846/93
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 70948/94;
now Australia Serial No. AU ▇▇▇▇▇▇ (abandoned)
UNGR-0425 Canada App. No. 2,164,843 (abandoned)
UNGR-0426 China App. 94192404.1 (abandoned)
UNGR-0427 EPO App. No. 94920019.0
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
-▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 501807/95
BLOCK MRI COPOLYMERS FAMILY
WWKMN Docket Series (UNGR 0045)
US 5,385,719; US 5,458,127; US 5,517,993
Other files: USSN 07/765,921 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0045)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 27524/92;
now ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,116,357 (abandoned)
UNGR-0238 EPO App. No. 92921259.5 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (abandoned)
UNGR-0249 Monaco (abandoned)
-▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
UNGR-0252 Sweden (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
UNGR-0254 Japan App. No. 506396/93
MEMSOMES FAMILY
WWKMN Docket Series (UNGR 0066)
US 5,312,617; US 5,466,438; US 5,624,662 US 5,762,910; US 6,010,682
Other files: USSN 07/704,542 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0066)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 19987/92;
now Australia Serial ▇▇. ▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,102,605 (abandoned)
UNGR-0217 EPO App. No. 92912134.1 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
UNGR-0222 Great Britain (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (abandoned)
UNGR-0227 Monaco (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
UNGR-0230 Sweden (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇/▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 30536/95;
now Australia Serial No. 678724 (abandoned)
NANOGELS
-8-
WWKMN Docket Series (UNGR 0089)
US 5,358,702; US 5,976,500
Other files: USSN 07/794,437 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0089)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 28940/92;
now ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇(▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,121,681 (abandoned)
UNGR-0262 EPO App. No. 92922870.8 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
UNGR-0267 Great Britain (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (abandoned)
UNGR-0273 Monaco (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
UNGR-0276 Sweden (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
UNGR-0278 Japan App. No. 509251/93 (abandoned)
AEROCREME
WWKMN Docket Series (UNGR 0343)
US 5,733,572
Pending: USSN 08/909,157
Other files: USSN 08/159,674 (abandoned)
FOREIGN -
-9-
Corresponding to WWKMN Docket Series (UNGR-0343)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. ▇▇. ▇▇▇▇▇/▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,177,713
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 94194349.6
UNGR-0551 EPO App. No. 95908414.6
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
UNGR-0556 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 515763/95
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 10043/99 (abandoned)
MRI HYBRIDS
(Prosecuted by ▇. ▇▇▇▇▇▇▇, Esq.)
US 5,407,657*
* Also include foreign equivalents Australia - AU ▇▇▇▇▇▇▇ and Europe - EPO
822835
SUNSCREEN
WWKMN Docket Series (UNGR 0469)
US 5,824,312
Other files: USSN 08/209,531 (abandoned)
-10-
FOREIGN -
WWKMN Docket Series (UNGR-0469)
No foreign filing corresponding to UNGR-0469
BIOPSY DEVICE
WWKMN Docket Series WNGR 0540)
US 5,628,327; US 6,O 13,035
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0540)
No foreign filing corresponding to UNGR-0540
-11-
TRANSDUCERDRUG DELIVERY
WWKMN Docket Series fUNGR 06221
US 5,558,092
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0622)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 58756/96;
now ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,220,756 (abandoned)
UNGR-0923 China App. No. 96194441.2 (abandoned)
UNGR-0924 EPO App. NO. 96920466.8
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-0930 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇/▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 44448/99
TOMORX
WWKMN Docket Series (UNGR 0477 and 0623)
US 5,736,121
US 5,874,062
Pending: USSN 081935,601
USSN 081968,776
Other files: 081247,656 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0477 and UNGR-0623)
Correspondinp to UNGR-0477
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 26013195;
now Australia Serial No. 700799; now Australia Patent ▇▇. ▇▇-▇-▇▇▇▇▇▇▇▇
(▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,188,557 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 95 193160.1 (abandoned)
UNGR-0603 EPO App. No. 95920616.0 (aandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
UNGR-0608 Great Britain (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇(▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ Monaco (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
UNGR-0618 Sweden (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 530494/95
Corresponding to UNGR-0623
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 26454/95;
now Australia Serial ▇▇. ▇▇▇▇▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 2,191,079 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 95 193274.8 (abandoned)
UNGR-0646 EPO App. No. 95921354.7 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
UNGR-0651 Great Britain (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (abandoned)
UNGR-0657 Monaco (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇ (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ (abandoned)
UNGR-0661 Sweden (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (abandoned)
UNGR-0663 Japan App. No. 530490/95
MRI AEROSOMES
WWKMN Docket Series (UNGR 0420)
US 5,922,304
Pending: USSN 09/272,468
Other files: USSN 08/212,553 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series KJNGR-0420)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ - closed
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - closed
UNGR-0580 EPO App. NO. 95914685.3
UNGR-058 1 Austria - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-0585 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
BIOPSY LEVELING DEVICE
WWKMN Docket Series (UNGR 0943)
US 6,030,348
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0943)
No foreign filing corresponding to UNGR-0943
FLUORINATED PRODRUGS
WWKMN Docket Series (UNGR 1114)
US 6,028,066
FOREIGN -
Correspondinq to WWKMN Docket Series (UNGR-1114)
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. NO. PCT/US98/07712
UNGR-1370 Australia-closed
UNGR-137 1 Brazil-closed
UNGR- 1372 Canada-closed
UNGR-1373 EPO'App. No. 98915610.4 - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇-▇▇▇▇▇▇
UNGR-1379 France-closed
UNGR-1380 Great Britain-closed
UNGR- 1381 Germany-closed
UNGR-13 82 Greece-closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ Monaco-closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ Portugal-closed
UNGR-1389 Spain-closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇-▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. P980102079
OPTOACOUSTIC DEVICE
WWKMN Docket Series WNGR 1278)
US 5,977,538
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-1278)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ EPO App. No. 99921767.2
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
UNGR-1564 France
UNGR-1565 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇
MRI FOCUSED SURGICAL ULTRASOUND
WWKMN Docket Series WNGR 0476)
US 6,088,613
FOREIGN -
Corresponding to WWKMN Docket Series WNGR-0476)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. ▇▇. ▇▇▇▇▇/▇▇ (▇▇▇▇▇▇▇▇▇)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No.2,214,855 (abandoned)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 96192434.9
UNGR-0768 EPO App. NO. 96908679.2
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
UNGR-0772 France
UNGR-0773 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-0780 ▇▇▇▇▇▇▇▇▇▇▇
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-0783 Sweden
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 527700196
SILICON ARNPHIPHILES
WWKMN Docket Series (UNGR 0880)
Pending: USSN 08/706,824
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0880)
No foreign filing corresponding to ▇▇▇▇-▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇/▇▇▇▇▇▇▇▇▇▇
WWKMN Docket Series WNGR 0917)
Pending: USSN 081841,169
Other files: USSN 08/640,554 (abandoned)
USSN 08/785,661 (abandoned)
FOREIGN-
Corresponding to WWKMN Docket Series (UNGR-0917)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 27490197
UNGR-1124 Canada App. No. 2,252,617
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - closed
UNGR-1126 EPO App. NO. 97921460.8
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-1142 Sweden
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 539185197
UNGR-1145 Brazil - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇. ▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
UNGR-1150 Russian Federation - closed
▇▇▇▇-▇▇▇ ▇ ▇▇▇▇▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ App. No. 86106635
DRUG DELIVERY TO INFLAMMED TISSUE
WWKMN Docket Series (UNGR 0975)
Pending: USSN 081823,791
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0975)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-1292 EPO App. NO. 98908866.1
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-1298 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 533386198
UNGR-1311 S. Korea
CHARGED LIPID AGGREGATES
WWKMN Docket Series (UNGR 0976)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0976)
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. P980101234
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇
UNGR-1315 Brazil
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-1318 EPO App. NO. 98906695.6
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-1324 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
UNGR-1337 S. Korea
OXYGEN DELIVERY
WWKMN Docket Series (UNGR 0999)
Pending: USSN 081877,826
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-0999)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
UNGR-1456 EPO App. NO. 98928973.1
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-1463 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ Japan-closed
STEROID PRODRUGS
WWKMN Docket Series (UNGR 1003)
Pending: USSN 08/85 1,780
-21-
USSN 09/496,761
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-1003)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ - closed
UNGR-1345 Brazil - closed
UNGR-1346 Canada - closed
UNGR-1347 EPO App. No. 98915571.8 - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
UNGR-1354 Great Britain - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇ ▇ ▇▇▇▇▇▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. P980102078 (abandoned)
-22-
SOLID MATRIX DRUGS
WWKMN Docket Series (UNGR 1394)
Pending: USSN 09/075,477
Other files: USSN 60/046,379 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-1394)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ - closed
-▇▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - closed
UNGR-1430 EPO App. No. 98921109.9
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-1437 Great Britain
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
UNGR-1441 Italy
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ - closed
UNGR-1449 Japan - closed
UNGR-1450 S. Korea - closed
▇▇▇▇-▇▇▇ ▇ ▇▇▇ ▇▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. ▇▇▇▇▇▇▇▇▇▇
UNGR-1453 Chile App. No. 1035/98
-24-
TARGETING FOR DIAGNOSIS OF ATRIAL FIBRILLATION
WWKMN Docket Series (UNGR 1173)
Pending: USSN 081932,273
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-1173)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇ ▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇ 19.2
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-1508 Great Britain
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇
UNGR- 15 13 Luxembourg - closed
▇▇▇▇-▇▇ ▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇ ▇▇ ▇▇▇▇▇ - closed
▇▇▇▇- ▇▇▇▇ ▇▇▇▇▇▇ - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ - closed
ULTRASOUND GENE UPREGULATION
WWKMN Docket Series (UNGR 1196)
Pending: USSN 08/971,540
FOREIGN-
Corresponding to WWKMN Docket Series (UNGR-1196)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
UNGR-I 527 Australia - closed
UNGR- ▇▇▇▇ ▇▇▇▇▇▇ - closed
-25-
UNGR-1529 EPO App. No. 98957720.0 - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - closed
UNGR-153 1 Great Britain - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - closed
UNGR-1533 Japan - closed
OPTOACOUSTIC AGENTS
WWKMN DOCKET SERIES (UNGR 1224)
PENDING: USSN 081993,165
FOREIGN -
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇
UNGR-1538 EPO App. No. 98964127.9
UNGR-1539 France
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
UNGR-1542 Japan
NUCLEAR LOCALIZATION DRUG DELIVERY
WWKMN DOCKET SERIES WNGR 1229)
PENDING: USSN 091294,623
FOREIGN -
▇▇▇▇-▇▇▇▇ ▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
UNGR-1591 Italy
ROBOTIC SONOPORATION AND MULTIMODAL ENERGY APPLICATION
WWKMN DOCKET SERIES (UNGR 1477)
PENDING: USSN 09/291,502
FOREIGN -
26
Corresponding to WWKMN Docket Series (UNGR-1477)
No foreign filing corresponding to UNGR-1477
INFUSION OF BIOACTIVE AGENTS
WWKMN Docket Series (UNGR 1580)
Pending: USSN 09/413,110
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-1580)
Foreign filing deadline October 6,2000
METHODS FOR QUANTITATING LIGAND BINDING TO THROMBUS (PROVISIONAL)
(▇. ▇▇▇▇▇▇▇ Prosecution)
Pending: USSN 60/118,551
TARGETED THROMBOLYTICS
(▇. ▇▇▇▇▇▇▇ Prosecution)
Pending: USSN 091371,193
27
EXHIBIT F
{ISSUED and PENDING US Patents followed by Foreign Files (if any)}
CATIONIC LIPIDS
WWKMN Docket Series WNGR 0569)
US 5,830,430; US 6,056,938
Pending: USSN 091244,083
USSN 091540,448
FOREIGN -
Corresponding to WWKMN Docket Series KJNGR-0569)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ App. No. 49 138196 (abandoned)
UNGR-0790 Canada App. No. 2,213,417
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No, 96192058.0
UNGR-0792 EPO App. NO. 9690535 1.1
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
UNGR-0796 France
UNGR-0797 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 525700196
ACOUSTICALLY ACTIVE LIPOSPHERES
WWKMN Docket Series NNGR 1338)
Pending: USSN 091075,343
-1-
Other files: USSN 60/046,379 (abandoned)
FOREIGN -
Corresponding to WWKMN Docket Series (UNGR-1338)
▇▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇. ▇▇. ▇▇▇/▇▇▇▇/▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ - closed
UNGR-1398 Brazil - closed
UNGR-1399 Canada - closed
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - closed
UNGR-1401 EPO App. No. 98926033.6
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-1408 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 549372198
UNGR-142I S. Korea - closed
UNGR-1422 New Zealand - closed
UNGR-1423 ▇▇▇▇▇▇▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. ▇▇. ▇▇▇▇/▇▇
-▇-
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ - closed
UNGR-1401 EPO App. NO. 98926033.6
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
UNGR-1408 Great Britain
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. No. 549372198
UNGR-1421 S. Korea - closed
UNGR-1422 New Zealand - closed
UNGR-1423 ▇▇▇▇▇▇▇▇▇ ▇▇▇. ▇▇. ▇▇▇▇▇▇▇▇▇▇
▇▇▇▇-▇▇▇▇ ▇▇▇▇▇ App. ▇▇. ▇▇▇▇/▇▇
-▇-
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ TO ASSIGNMENT, ASSUMPTION AND LICENSE AGREEMENT
THIS AMENDMENT to the Assignment, Assumption and License Agreement dated as
of October 7, 1999 (as amended by the amendment dated July 31, 2000, hereinafter
collectively the "Agreement") by and between IMARX, LLC, an Arizona limited
liability company ("Purchaser") and IMARX PHARMACEUTICAL CORP., an Arizona
corporation ("Seller") is entered into and effective April 1, 2002 by and
between IMARX THERAPEUTICS, INC., successor in interest to Purchaser ("ImaRx")
and ▇▇▇▇▇▇▇-▇▇▇▇▇ Squibb Medical Imaging, Inc. ("BMS"), successor in interest to
Seller. Capitalized terms used but not otherwise defined herein have the
meanings assigned to them in the Agreement.
RECITALS
A. Purchaser and Seller entered into the Agreement as of October 7, 1999.
Thereafter, Seller was merged into DuPont Contrast Imaging, Inc.
▇. ▇▇▇▇▇▇ Contrast Imaging, Inc. was acquired by ▇▇▇▇▇▇▇-▇▇▇▇▇ Squibb
Company on October 1, 2001 and the name of DuPont Contrast Imaging, Inc. was
changed to ▇▇▇▇▇▇▇-▇▇▇▇▇ Squibb Medical Imaging, Inc.
C. The parties now wish to amend Exhibit A and Exhibit B of the Agreement
to delete certain Category II Assets and to provide for additional Category III
Assets.
NOW, THEREFORE, in consideration of the foregoing premises and of the
agreements and covenants set forth in the Agreement, the parties agree as
follows.
AGREEMENT
1. Assignment of Assets. Attached hereto is Attachment A. The parties agree
that the assets set forth in Attachment A are Category III Assets, and Exhibit A
is hereby amended to include the assets set forth in Attachment A. BMS will
execute any other or further documents reasonably deemed necessary to reflect
the transfer and assignment of the assets set forth in Attachment A to ImaRx in
accordance with the terms of the Agreement. Exhibit B is hereby amended to
delete the assets set forth in Attachment A.
2. ImaRx shall have no obligation to prosecute or maintain any asset in
Attachment A either within CEDUI or outside CEDUI, provided however, that prior
to abandoning any asset in Attachment A, ImaRx shall give BMS at least 15
business days written notice of its intention to do so. Upon notice by BMS that
it wishes to acquire any such asset from ImaRx, ImaRx will assign the asset to
BMS, transfer any files or other documents relating to the asset to BMS, and BMS
will thereafter be solely responsible for prosecution or maintenance of the
asset, including
BMS-ImaRx -4-
Second Amendment to Assignment, Assumption and License Agreement
all costs associated therewith. Any such asset assigned to BMS shall be a
Category II Asset subject to the license set forth in Section 4 of the
Agreement, and BMS shall only have rights under such asset within the CEDUI
field of use.
3. The second sentence of Section 4 of the Agreement is hereby deleted and
replaced by the following:
Seller also grants to Purchaser the right to file and prosecute divisional,
continuation and continuation-in-part applications for patent claims
relating solely to fields of use outside of the CEDUI field of use arising
from patent applications included within Category II Assets, provided that
Purchaser will be solely responsible for all costs and expenses incurred in
connection with such filing and prosecution and further provided that
Purchaser will have no right to practice, transfer, license, or otherwise
exploit any patents issuing from such applications within CEDUI. Purchaser
shall provide notice to the Seller of the filing of any such patent
application, the filing date and the Category II patent(s) or patent
application(s) to which such patent application claims priority and
identify the assignee of such patent application. Where possible, Purchaser
shall be the assignee of such patent applications (and patents issuing
thereon), unless such assignment will adversely effect the patent rights
involved (for example, in the case of a terminal disclaimer). Where
Purchaser is the assignee, such patent applications (and patents issuing
thereon) shall be Category III Assets, subject to the license set forth in
Section 5. Where Seller is the assignee, such patent applications (and
patents issuing thereon) shall be Category II Assets, subject to the
foregoing provisions of this Section 4.
BMS-ImaRx -5-
Second Amendment to Assignment, Assumption and License Agreement
4. All applications for patents filed by ImaRx as of the date of this
Amendment pursuant to Section 4 of the Agreement which are Category III assets
are identified in Attachment C hereof.
5. No Warranty. BMS believes that it has not assigned, conveyed, licensed
or otherwise transferred any interest in any asset listed on Attachment A to any
other person or entity. Notwithstanding anything to the contrary, BMS makes no
warranty, express or implied, regarding the assets listed on Attachment A and
specifically disclaims any responsibility for any action or inaction regarding
the prosecution of any patents or any other protection of any intellectual
property embodied or reflected in Attachment A during the period from the date
of the Agreement to the date of this Amendment.
6. Attachment B. Attached hereto is Attachment B. The assets set forth in
Attachment B are Category II assets. ImaRx agrees to be responsible for the
prosecution and maintenance of the patents and patent applications set forth in
Attachment B, including all costs associated therewith. In the event that ImaRx
wants to abandon any patent or patent application set forth in Attachment B,
ImaRx shall provide BMS at least 15 business days prior written notice of its
intention to do so. BMS shall then have the right to assume responsibility for
the prosecution and maintenance of such patent or patent application and the
costs associated therewith. Upon request by BMS, ImaRx will transfer any files
or other documents relating to such patent or patent application and otherwise
cooperate with BMS to enable BMS to assume responsibility for such patent or
patent application.
7. Section 5. The following is hereby added to the end of Section 5 of the
Agreement:
Purchaser also grants to Seller the right to file and prosecute divisional,
continuation and continuation-in-part applications for patent claims relating
solely to the CEDUI field of use arising from patent applications included
within Category III Assets, provided that Seller will be solely responsible for
all costs and expenses incurred in connection with such filing and prosecution
and further provided that Seller will have no right to practice, transfer,
license, or otherwise exploit any patents issuing from such applications outside
of the CEDUI field of use. Seller shall provide notice to the Purchaser of the
filing of any such patent application, the filing date and the Category III
patent(s) or patent application(s) to which such patent application claims
priority and identify the assignee of such patent application. Where possible,
Seller shall be the assignee of such patent applications (and patents issuing
thereon), unless such assignment will adversely effect the patent rights
involved (for example, in the case of a terminal disclaimer). Where Seller is
the assignee, such patent applications (and patents issuing thereon) shall be
Category II Assets, subject to the license set forth in Section 4. Where
Purchaser is the assignee, such patent applications (and patents issuing
thereon) shall be Category III Assets, subject to the foregoing provisions of
this Section 5.
8. Continued Effect. Except as amended hereby, the Agreement remains in
full force and effect.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed as of the day and year first above written.
▇▇▇▇▇▇▇-▇▇▇▇▇ SQUIBB
MEDICAL IMAGING, INC.
By: /s/ M. ▇▇▇▇ ▇▇▇▇▇▇▇▇ By: /s/ ▇▇▇▇ ▇▇▇▇▇▇▇
---------------------------- ----------------------------
BMS-ImaRx -6-
Second Amendment to Assignment, Assumption and License Agreement
Its: President Its: Sr. Director, Business Development
Attachment A BMS-ImaRx Second Amendment Agreement
ATTACHMENT A
BMS-0250 FAMILY
BMS-0253 Brazil Serial No. PI 9609343-9; Filed November 20, 1997
[Formerly UNGR-0811] (via PCT/US96/07887, Filed June 6, 1996). Method and
FF of BMS-0250 Apparatus for Making Gas-Filled Vesicles of Optimal Size.
BMS-0276 Mexico - Serial No. 9709717; Filed December 5, 1997 (via
[Formerly UNGR-0858] PCT/US96/07887; Filed June 6, 1996). Method and Apparatus
FF or BMS-0250 for Making Gas-Filled Vesicles of Optimal Size.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ - Application No. P 96 0102914 (formerly
[Formerly UNGR-0859] 336,835); Filed June 5, 1996. Method and Apparatus for
FF or BMS-0250 Making Gas-Filled Vesicles of Optimal Size.
BMS-0279 Chile Serial No. 986-96, Filed June 5, 1996. Method and
[Formerly ▇▇▇▇-▇▇▇▇] ▇▇▇▇▇▇▇▇▇ for Making Gas-Filled Vesicles of Optimal Size.
FF or BMS-0250
Attachment A, Page 1 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0441 FAMILY
BMS-0442 EPO - Application No. 98307421.2; Filed September 14,
[Formerly UNGR-1478] 1998. Thermal Preactivation of Gaseous Precursor Filled
FF of BMS-0441 Compositions.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1479] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1480] Precursor Filled Compositions.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1481] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1482] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
BMS-0447 Finland (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1483] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1484] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
Attachment A, Page 2 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0449 Great Britain (via EPO) - Thermal Preactivation of
[Formerly UNGR-1485] Gaseous Precursor Filled Compositions.
EP Designated
Country of BMS-0442
BMS-0450 Germany (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1486] Precursor Filled Compositions.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1487] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1488] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
BMS-0453 Italy (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1489] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1490] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
BMS-0455 Monaco (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1491] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1492] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
Attachment A, Page 3 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0457 Portugal (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1493] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
BMS-0458 Spain (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1494] Precursor Filled Compositions.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1495] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Thermal Preactivation of Gaseous
[Formerly UNGR-1496] Precursor Filled Compositions.
EP Designated
Country of BMS-0442
BMS-0003 FAMILY
BMS-0016 European Patent No. 0511273; Granted May 19, 1999.
[Formerly UNGR-0029] EPO - Application No. 91902857.1; (via PCT/US90/07500;
FF of BMS-0003 Filed December 19, 1990).
Liposomes As Contrast Agents For Ultrasonic Imaging And
Methods For Preparing The Same.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ - (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0030] 1990) Liposomes As Contrast Agents For Ultrasonic And
EP Designated Methods For Preparing The Same.
Country of BMS-0016
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0031] 19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated And Methods For Preparing The Same.
Country of BMS-0016
Attachment A, Page 4 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0032] 19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated And Methods For Preparing The Same.
Country of BMS-0016
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0033] 19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated And Methods For Preparing The Same.
Country of BMS-0016
BMS-0021 Germany (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0034] 19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated And Methods For Preparing The Same.
Country of BMS-0016
BMS-0022 Great Britain (via EPO) (Serial No. 91902857.1 filed
[Formerly UNGR-0035] December 19, 1990.) Liposomes As Contrast Agents For
EP Designated Ultrasonic And Methods For Preparing The Same.
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0036] 19, 1990.) Liposomes As Contrast Agents For Ultrasonic
EP Designated And Methods For Preparing The Same.
Country of BMS-0016
BMS-0024 Italy (via EPO) (Serial No. 91902857.1 filed December 19,
[Formerly UNGR-0037] 1990.) Liposomes As Contrast Agents For Ultrasonic And
EP Designated Methods For Preparing The Same.
Country of BMS-0016
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO) (Serial No. 91902857.1 filed
[Formerly UNGR-0038] December 19, 1990.) Liposomes As Contrast Agents For
EP Designated Ultrasonic And Methods For Preparing The Same.
Country of BMS-0016
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) (Serial No.91902857.1; Filed
[Formerly UNGR-0039] December 19, 1990.) Liposomes As Contrast Agents For
EP Designated Ultrasonic And Methods For Preparing The Same.
Country of BMS-0016
Attachment A, Page 5 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0027 Spain (via EPO) (Serial No. 91902857.1; Filed December
[Formerly UNGR-0040] 19, 1990.) Liposomes as Contrast Agents for Ultrasonic
EP Designated and Methods for Preparing the Same.
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) (Serial No. 91902857.1 filed December
[Formerly UNGR-0041] 19, 1990.) Liposomes as Contrast Agents for Ultrasonic
EP Designated and Methods for Preparing the Same.
Country of BMS-0016
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) (Serial No.91902857.1; Filed
[Formerly UNGR-0042] December 19, 1990.) Liposomes as Contrast Agents for
EP Designated Ultrasonic and Methods for Preparing the Same.
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇ ▇▇▇▇ Patent No. HK 1013625; Issued April 20, 2000.
[Formerly UNGR-1548] Hong Kong - Application No. 98114978.0 (via EPO
EP Designated Application No. 91902857.1) Filed December 23, 1998.
Country of BMS-0016 Liposomes As Contrast Agents For Ultrasonic And Methods
For Preparing The Same.
BMS-0439 FAMILY
BMS-0645 U.S. Serial No. 10/113577; Filed April 2, 2002.
CON of BMS-0439 Ultrasound Imaging And Treatment.
[Formerly UNGR-1032]
BMS-0489 EPO - Application No. 97202273.5; Filed May 4, 1992.
[Formerly UNGR-1156] Methods for Providing Localized Therapeutic Heat to
Biological Tissues and Fluids.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Methods for Providing Localized
[Formerly UNGR-1157] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Methods for Providing Localized
[Formerly UNGR-1158] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
Attachment A, Page 6 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Methods for Providing Localized
[Formerly UNGR-1159] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Methods for Providing Localized
[Formerly UNGR-1160] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
BMS-0494 Great Britain (via EPO) - Methods for Providing Localized
[Formerly UNGR-1161] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
BMS-0495 Germany (via EPO) - Methods for Providing Localized
[Formerly UNGR-1162] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
BMS-0496 Greece (via EPO) - Methods for Providing Localized
[Formerly UNGR-1163] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
BMS-0497 Italy (via EPO) - Methods for Providing Localized
[Formerly UNGR-1164] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO) - Methods for Providing Localized
[Formerly UNGR-1165] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
BMS-0499 Monaco (via EPO) - Methods for Providing Localized
[Formerly UNGR-1166] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
Attachment A, Page 7 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Methods for Providing Localized
[Formerly UNGR-1167] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
BMS-0501 Spain (via EPO) - Methods for Providing Localized
[Formerly UNGR-1168] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Methods for Providing Localized
[Formerly UNGR-1169] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of BMS-0489
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Methods for Providing Localized
[Formerly UNGR-1170] Therapeutic Heat to Biological Tissues and Fluids.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇ (via PCT) - Application No. 184624/97; Filed June
[Formerly UNGR-1171] 26, 1997. Method for Hypothermic Potentiation of Tissue.
BMS-0506 Australian Patent No. 694973; Issued/granted November 19,
[Formerly UNGR-1034] 1998. Australia - Application No. 12212/97; Filed January
17, 1997. Method for Hyperthermic Potentiation of
Tissues.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - Application No. 2,211,517; Filed September 9,
[Formerly UNGR-1155] 1997. Methods for Providing Localized Therapeutic Heat to
Biological Tissues and Fluids.
BMS-0221 FAMILY
BMS-0224 Russian Federation - Serial No. 97118412, November 5,
[Formerly UNGR-0884] 1997 (via PCT/US96/04208; Filed March 27, 1996). Novel
FF of BMS-0221 Compositions of Lipids and Stabilizing Materials.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ (via PCT) - Serial No. P96 01 02022; Filed
[Formerly UNGR-0908] April 2, 1996. Novel Compositions of Lipids and
Stabilizing Materials.
Attachment A, Page 8 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
FF of BMS-0221
BMS-0249 Chile (via PCT) - Serial No. 528-96, Filed April 3, 1996.
[Formerly UNGR-0909] Novel Compositions of Lipids and Stabilizing Materials.
FF of BMS-0221
BMS-0343 FAMILY
BMS-0347 EPO Application No. 97920281.9; Filed April 2, 1997 (via
[Formerly UNGR-1046] PCT/US97/05908). Process for Preparing an Optimally
FF of BMS-0343 Dispersible Lipid Blend.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1047] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1048] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1049] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
BMS-0351 Finland (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1050] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
Attachment A, Page 9 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0352 France (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1051 Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
BMS-0353 Great Britain (via EPO) - Process for Preparing an
[Formerly UNGR-1052] Optimally Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
BMS-0354 Germany (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1053] Dispersible Lipid Blend.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1054] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1055] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
BMS-0357 Italy (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1056] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1057] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
BMS-0359 Monaco (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1058] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
Attachment A, Page 10 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Process for Preparing an
[Formerly UNGR-1059] Optimally Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
BMS-0361 Portugal (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1060] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
BMS-0362 Spain (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1061] Dispersible Lipid Blend.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Process for Preparing an Optimally
[Formerly UNGR-1062] Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Process for Preparing an
[Formerly UNGR-1063] Optimally Dispersible Lipid Blend.
EP Designated
Country of BMS-0347
BMS-0400 FAMILY
DUP-0407 EPO - Application No. 97946447.6; Filed November 3, 1997
[Formerly UNGR-1237] (via PCT/US97/19900). Novel Compositions of
FF of DUP-0399 and Perfluorinated Ethers and the Like and Their Use as
DUP-0400 Contrast Media for Diagnostic Imaging and in Other
Applications.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1238] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1239] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
Attachment A, Page 11 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1240] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
DUP-0411 Finland (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1241] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1242] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
DUP-0413 Great Britain (via EPO) - Novel Compositions of
[Formerly UNGR-1243] Perfluorinated Ethers and the Like and Their Use as
FF of DUP-0399 and Contrast Media for Diagnostic Imaging and in Other
DUP-0400 Applications.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1244] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1245] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1246] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
▇▇▇-▇▇▇▇ ▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1247] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 and Diagnostic Imaging and in Other Applications.
DUP-0400
Attachment A, Page 12 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO) - Novel Compositions of
[Formerly UNGR-1248] Perfluorinated Ethers and the Like and Their Use as
FF of DUP-0399 Contrast Media for Diagnostic Imaging and in Other
and DUP-0400 Applications.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1249] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 Diagnostic Imaging and in Other Applications.
and DUP-0400
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Novel Compositions of
[Formerly UNGR-1250] Perfluorinated Ethers and the Like and Their Use as
FF of DUP-0399 Contrast Media for Diagnostic Imaging and in Other
and DUP-0400 Applications.
DUP-0421 Portugal (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1251] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 Diagnostic Imaging and in Other Applications.
and DUP-0400
▇▇▇-▇▇▇▇ ▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1252] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 Diagnostic Imaging and in Other Applications.
and ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Novel Compositions of Perfluorinated
[Formerly UNGR-1253] Ethers and the Like and Their Use as Contrast Media for
FF of DUP-0399 Diagnostic Imaging and in Other Applications.
and DUP-0400
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Novel Compositions of
[Formerly UNGR-1254] Perfluorinated Ethers and the Like and Their Use as
FF of DUP-0399 Contrast Media for Diagnostic Imaging and in Other
and DUP-0400 Applications.
Attachment A, Page 13 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0139 FAMILY
BMS-0140 U.S. Serial No. 08/485,998; Filed June 7, 1995; Novel
[Formerly UNGR-0692] Therapeutic Delivery Systems. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇,
DIV of BMS-0139 ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, Guanli Wu.
BMS-0141 PCT Publication WO 94/28874, published December 22, 1994
[Formerly UNGR-0483] PCT/US94/05633; filed May 19, 1994. Novel Therapeutic
FF of BMS-0139 Delivery Systems. Inventors: ▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇,
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇,
and Guanli Wu. Also claiming priority from UNGR-0343,
U.S. Serial No. 159,674 filed 11/30/93 and U.S. Serial
No. 159,687 filed 11/30/93.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Patent No. AU ▇▇▇▇▇▇; Granted May 19, 1994.
[Formerly ▇▇▇▇-▇▇▇▇] ▇▇▇▇▇▇▇▇▇ - Application No. 69537/94, Filed May 19, 1994
FF of BMS-0139 (via PCT/US94/05633 filed May 19, 1994). Novel
Therapeutic Delivery Systems. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇,
▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, and Guanli Wu.
BMS-0143 Canada Application No. 2,164,846; Filed May 19, 1994.
[Formerly UNGR-0485] (via PCT/US94/05633 filed 5/19/94. Novel Therapeutic
FF of BMS-0139 Delivery Systems. Inventors: ▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇,
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇,
and Guanli Wu.
BMS-0162 Japan - Application No. 501811/95 (PCT/US94/05633 filed
[Formerly UNGR-0504] May 19, 1994). Novel Therapeutic Delivery Systems.
FF of BMS-0139 Inventors: ▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, and Guanli Wu.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Patent No. 732440; Issued August 9, 2001.
[Formerly ▇▇▇▇-▇▇▇▇] ▇▇▇▇▇▇▇▇▇ - Application No. 88406/98, Filed October 9,
DIV of UNGR-0484; 1998. Novel Therapeutic Delivery Systems. Inventors: Evan
FF of UNGR-0483; ▇. ▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇
FF of BMS-0139 ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, and Guanli Wu.
Attachment A, Page 14 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0280 FAMILY
BMS-0280 U.S. Patent No. 5,997,898; Issued December 7, 1999. U.S.
[Formerly UNGR-0625] Serial No. 08/465,868 filed June 6, 1995. Stabilized
Compositions of Fluorinated Amphiphiles as Contrast
Agents for Ultrasound.
BMS-0281 International Publication No. WO 96/07813; Published
[Formerly UNGR-0835] December 12, 1996.
FF of BMS-0280 PCT - Application No. PCT/US96/07813; Filed May 28, 1996.
Gas Filled Liposomes and Gas Bubbles Coated with
Perfluorocarbon-Based Surfactants.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Patent No. 715681; Issued May 25, 2000.
[Formerly ▇▇▇▇-▇▇▇▇] ▇▇▇▇▇▇▇▇▇ - Serial No. 715681 (formerly Application No.
FF of BMS-0280 59360/96; Filed May 28, 1996 (via PCT/US96/07813).
Gas Filled Liposomes and Gas Bubbles Coated with
Perfluorocarbon-Based Surfactants.
BMS-0284 China - Application No. 961 94248.7; Filed May 28, 1996
[Formerly UNGR-0839] (via PCT/US96/07813). Gas Filled Liposomes and Gas
FF of BMS-0280 Bubbles Coated with Perfluorocarbon-Based Surfactants.
BMS-0285 EPO - Application No. 96916685.9; Filed May 28, 1996 (via
[Formerly UNGR-0840] PCT/US96/07813). Gas Filled Liposomes and Gas Bubbles
FF of BMS-0280 Coated with Perfluorocarbon-Based Surfactants.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0841] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of
BMS-0285
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0842] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of
BMS-0285
Attachment A, Page 15 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0843] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0844] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
BMS-0290 Great Britain (via EPO). Gas Filled Liposomes and Gas
[Formerly UNGR-0845] Bubbles Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
BMS-0291 Germany (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0846] Coated with Perfluorocarbon-Based Surfactants
FF or ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0847] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0848] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
BMS-0294 Italy (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0849] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO). Gas Filled Liposomes and Gas
[Formerly UNGR-0850] Bubbles Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
Attachment A, Page 16 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0296 Monaco (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0851] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO). Gas Filled Liposomes and Gas
[Formerly UNGR-0852] Bubbles Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
BMS-0298 Portugal (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0853] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
BMS-0299 Spain (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0854] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0855] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO). Gas Filled Liposomes and Gas
[Formerly UNGR-0856] Bubbles Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇ - Application No. 500770/97; Filed May 28, 1996
[Formerly UNGR-0857] (via PCT/US96/07813). Gas Filled Liposomes and Gas
FF of BMS-0280 Bubbles Coated with Perfluorocarbon-Based Surfactants.
BMS-0303 Finland (via EPO) - Gas Filled Liposomes and Gas Bubbles
[Formerly UNGR-0971] Coated with Perfluorocarbon-Based Surfactants
EP Designated
Country of BMS-0285
BMS-0306 FAMILY
BMS-0307 U.S. Serial No. 09/218,660; Filed December 22, 1998.
Attachment A, Page 17 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
[Formerly UNGR-1520] Novel Targeted Compositions for Diagnostic and
Therapeutic Use.
BMS-0308 International Publication No. WO 96/40285; Published
[Formerly UNGR-0945] December 19, 1996. PCT - Serial No. PCT/US96/09938; Filed
FF of BMS-0306 June 6, 1996. Novel Targeted Compositions for Diagnostic
and Therapeutic Use.
BMS-0309 China - Application No. 96 1 94499.4; Filed June 6, 1996
[Formerly UNGR-0946] (via PCT/US96/09938). Novel Targeted Compositions for
FF of BMS-0306 Diagnostic and Therapeutic Use.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Patent No. 709562; Issued December 16, 1999.
[Formerly ▇▇▇▇-▇▇▇▇] ▇▇▇▇▇▇▇▇▇ - Serial No. 709562 (formerly Application No.
FF of BMS-0306 62703/96); Filed June 6, 1996 (via PCT Serial No.
PCT/US96/09938). Novel Targeted Compositions for
Diagnostic and Therapeutic Use.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - Application No. 2,218,541; Filed June 6, 1996
[Formerly UNGR-0948] (via PCT/US96/09938). Novel Targeted Compositions for
FF of BMS-0306 Diagnostic and Therapeutic Use.
BMS-0312 EPO - Application No. 96921486.5; Filed June 6, 1996 (via
[Formerly UNGR-0949] PCT/US96/09938). Novel Targeted Compositions for
FF of BMS-0306 Diagnostic and Therapeutic Use.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0950] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
Attachment A, Page 18 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0951] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0952] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
BMS-0316 Finland (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0953] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0954] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
BMS-0318 Great Britain (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0955] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
BMS-0319 Germany (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0956] Diagnostic and Therapeutic Use.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0957] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0958] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
Attachment A, Page 19 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0322 Italy (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0959] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0960] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
BMS-0324 Monaco (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0961] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0962] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
BMS-0326 Portugal (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0963] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
BMS-0327 Spain (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0964] Diagnostic and Therapeutic Use.
EP Designated
Country of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0965] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Targeted Compositions for
[Formerly UNGR-0966] Diagnostic and Therapeutic Use.
EP Designated
Country of BMS-0312
Attachment A, Page 20 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0330 Japan - Application No. 502099/97; Filed June 6, 1996
[Formerly UNGR-0967] (via PCT/US96/09938). Novel Targeted Compositions for
FF of BMS-0306 Diagnostic and Therapeutic Use.
BMS-0463 FAMILY
BMS-0463 U.S. Serial No.09/243,640; Filed February 3, 1999. Novel
[Formerly UNGR-1550] Methods of Imaging and Treatment with Targeted
Compositions.
BMS-0488 International Publication No. WO 00/45856; Published
FF of BMS-0463 August 10, 2000. PCT - Application No. PCT/US00/02620;
Filed February 2, 2000. Novel Methods of Imaging and
Treatment with Targeted Compositions.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Application ▇▇. ▇▇▇▇▇/▇▇ (▇▇▇ ▇▇▇/▇▇▇▇/▇▇▇▇▇;
▇▇ ▇▇ ▇▇▇-▇▇▇▇; Filed February 2, 2000). Novel Methods of Imaging and
BMS-0462 Treatment with Targeted Compositions. Inventors: ▇▇▇▇ ▇.
▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0598 Canada Application No. 2,362,200 (via PCT/US00/02620;
FF of BMS-0463; Filed February 2, 2000). Novel Methods of Imaging and
BMS-0462 Treatment with Targeted Compositions. Inventors: ▇▇▇▇ ▇.
▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0599 EPO Application No. 00914480.9 (via PCT/US00/02620; Filed
FF of BMS-0463; February 2, 2000). Novel Methods of Imaging and Treatment
BMS-0462 with Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and
▇▇▇▇▇▇ ▇▇.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463; with Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and
BMS-0462 ▇▇▇▇▇▇ ▇▇.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463; with Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and
BMS-0462 ▇▇▇▇▇▇ ▇▇.
BMS-0602 Cyprus (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463; with Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and
BMS-0462 ▇▇▇▇▇▇ ▇▇.
Attachment A, Page 21 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463; Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0462
BMS-0604 Finland (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463; Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0462
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463; Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0462
BMS-0606 Great Britain (via EPO). Novel Methods of Imaging and
FF of BMS-0463; Treatment with Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇
BMS-0462 and ▇▇▇▇▇▇ ▇▇.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463; Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463; Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0462
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463; Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0462
BMS-0610 Italy (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463; Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0462
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463; with Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and
BMS-0462 ▇▇▇▇▇▇ ▇▇.
BMS-0612 Monaco (via EPO). Novel Methods of Imaging and Treatment with
FF of BMS-0463; Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0462
Attachment A, Page 22 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and
FF of BMS-0463; Treatment with Targeted Compositions. Inventors: ▇▇▇▇ ▇.
BMS-0462 ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0614 Portugal (via EPO). Novel Methods of Imaging and
FF of BMS-0463; Treatment with Targeted Compositions. Inventors: ▇▇▇▇ ▇.
BMS-0462 ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0615 Spain (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463; with Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and
BMS-0462 ▇▇▇▇▇▇ ▇▇.
BMS-0616 Sweden (via EPO). Novel Methods of Imaging and Treatment
FF of BMS-0463; with Targeted Compositions. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇ and
BMS-0462 ▇▇▇▇▇▇ ▇▇.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Methods of Imaging and
FF of BMS-0463; Treatment with Targeted Compositions. Inventors: ▇▇▇▇ ▇.
BMS-0462 ▇▇▇▇▇ and ▇▇▇▇▇▇ ▇▇.
BMS-0533 FAMILY
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ - Application No. 2,213,417 (via PCT Serial No.
[Formerly UNGR-0790] PCT/US96/01474; Filed January 29, 1996). Novel Cationic
FF of BMS-0533 Lipids and The Use Thereof.
BMS-0539 China - Serial No. 96192058.0 (via PCT Serial No.
[Formerly UNGR-0791] PCT/US96/01474; Filed January 29, 1996). Novel Cationic
FF of BMS-0533 Lipids and The Use Thereof.
BMS-0540 EPO- Serial No. 96905351.1 (via PCT Serial No.
[Formerly UNGR-0792] PCT/US96/01474; Filed January 29, 1996). Novel Cationic
FF of BMS-0533 Lipids and The Use Thereof.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0793] Thereof.
FF of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0794] Thereof.
FF of BMS-0533
Attachment A, Page 23 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0795] Thereof.
FF of BMS-0533
BMS-0544 France (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0796] Thereof.
FF of BMS-0533
BMS-0545 Great Britain (via EPO). Novel Cationic Lipids and The
[Formerly UNGR-0797] Use Thereof.
FF of BMS-0533
BMS-0546 Germany (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0798] Thereof.
FF of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0799] Thereof.
FF of BMS-0533
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0800] Thereof.
FF of BMS-0533
BMS-0549 Italy (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0801] Thereof.
FF of BMS-0533
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0802] Thereof.
FF of BMS-0533
BMS-0551 Monaco (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0803] Thereof.
FF of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0804] Thereof.
FF of BMS-0533
Attachment A, Page 24 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
BMS-0553 Portugal (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0805] Thereof.
FF of BMS-0533
BMS-0554 Spain (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0806] Thereof.
FF of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0807] Thereof.
FF of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO). Novel Cationic Lipids and The Use
[Formerly UNGR-0808] Thereof.
FF of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇ - Application No. 525700/96 (via PCT Serial No.
[Formerly UNGR-0809] PCT/US96/01474; Filed January 29, 1996). Novel Cationic
FF of BMS-0533 Lipids and The Use Thereof.
BMS-0558 FAMILY
BMS-0558 U.S. Serial No. 09/075,343; Filed May 11, 1998;
[Formerly UNGR-1338] Confirmation No. 3547. Novel Acoustically Active Drug
Based on UNGR-1118 Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
BMS-0559 International Publication No. WO 98/51284; Published
[Formerly UNGR-1396] November 19, 1998. PCT - PCT/US98/09569; Filed May 12,
FF of BMS-0558 1998. Novel Acoustically Active Drug Delivery Systems.
Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
BMS-0564 EPO Application No. 98926033.6 (via PCT/US98/09569; Filed
[Formerly UNGR-1401] May 12, 1998) - Novel Acoustically Active Drug Delivery
FF of BMS-0558 Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1402] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
Attachment A, Page 25 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1403] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1404] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1405] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0569 Finland (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1406] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1407] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0571 Great Britain (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1408] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0572 Germany (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1409] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0573 Greece (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1410] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1411] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0575 Italy (via EPO) - Novel Acoustically Active Drug Delivery
[Formerly UNGR-1412] Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
Attachment A, Page 26 of 27
Attachment A BMS-ImaRx Second Amendment Agreement
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1413] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0577 Monaco (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1414] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1415] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0579 Portugal (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1416] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0580 Spain (via EPO) - Novel Acoustically Active Drug Delivery
[Formerly UNGR-1417] Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
BMS-0581 Sweden (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1418] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ (via EPO) - Novel Acoustically Active Drug
[Formerly UNGR-1419] Delivery Systems. Inventor: ▇▇▇▇ ▇. ▇▇▇▇▇.
FF of BMS-0558
Attachment A, Page 27 of 27
Attachment B BMS-ImaRx Second Amendment Agreement
ATTACHMENT B
BMS-0596 U.S. Serial No. 09/901,934; Filed July 10, 2001. Gas
CON of BMS-0093 Filled Liposomes and their Use as Ultrasonic Contrast
Agents. Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇, Guanli Wu
BMS-0222 U.S. Serial No. 08/947,305; Filed October 8, 1997; Novel
[Formerly UNGR-1223] Compositions of Lipids and Stabilizing Materials.
DIV of ▇▇▇-▇▇▇▇
▇▇▇-▇▇▇▇ ▇.▇. Patent No. 5,542,935; Issued August 6, 1996.
[Formerly UNGR-0348] U.S. Serial No. 08/160,232; Filed November 30, 1993.
Novel Therapeutic Delivery Systems Related Applications.
Inventors: ▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, and
Guanli Wu.
Attachment B, Page 1 of 1
Attachment C BMS-ImaRx Second Amendment Agreement
ATTACHMENT C
UNGR-1600
DIV of BMS-0441 (formerly UNGR-1172)
U.S. Serial No. 09/813,484; Filed March 21, 2001
Novel Methods of Ultrasound Treatment Using Gas or Gaseous Precursor Filled
Compositions
UNGR-1632
DIV of BMS-0558 (formerly UNGR-1338)
U.S. Serial No. ____________________; Filed February 27, 2002
Novel Acoustically Active Drug Delivery Systems
UNGR-1633
DIV of BMS-0309 (formerly UNGR-0968); FF of BMS-0306 (formerly UNGR-0944)
China - Serial No. ▇▇ ▇ ▇▇▇▇▇.▇; Filed February 22, 2002
Novel Targeted Compositions for Diagnostic and Therapeutic Use
UNGR-1634
DIV of BMS-0140 (formerly UNGR-0692); DIV of BMS-0139 (formerly UNGR-0348)
U.S. Serial No. ____________________; Filed March 26, 2002
Novel Therapeutic Delivery Systems.
Attachment C, Page 1 of 1